

PhD position (4 years' funding) in the biology and treatment of Osteosarcoma

Osteosarcoma (OS) is an aggressive bone cancer mainly affecting children and young adults, characterised by severe genomic instability and a lack of targeted therapies. Using cutting-edge methods and unique primary patient-derived cell models, this project will seek to understand the fundamental biology of osteosarcoma and how this governs the response to existing and emerging chemotherapeutics. Our aim is to use these insights to identify new treatment strategies and apply them to preclinical models of osteosarcoma.

The PhD candidate will join the group of Dr. Chris Carnie and benefit from a thriving environment with close collaborations across the Universitätsklinikum Heidelberg (UKHD), EMBL Heidelberg and the Hopp-Children's Cancer Center (KiTZ). These include Prof. Andreas Kulozik and Prof. Matthias Hentze as part of the Molecular Medicine Partnership Unit (MMPU) research group "Translational RNA Biology", Prof. Dirk Theile (Clinical Pharmacology, UKHD) and beyond.

Key methodologies:

- Human 2D and 3D cell culture
- Gene editing using CRISPR/Cas9
- CRISPR screening
- Broad cell & molecular biology techniques

Your Profile:

- Enthusiastic about discovery and translational research
- Master's degree in Molecular Biology, Biochemistry or a related field
- Working knowledge of English
- Independent, structured, and precise working style
- Interest in interdisciplinary collaboration and modern research approaches

What We Offer:

- A varied role in an innovative and forward-thinking research environment
- A mutually supportive, open and friendly team
- Many opportunities for professional development

If you are excited about contributing to a dynamic field of research and actively shaping the understanding and treatment of osteosarcoma, we look forward to receiving your application. Please send your application, including a cover letter, CV and details of two referees to: christopherjames.carnie@med.uni-heidelberg.de by 6th June 2025.

We look forward to hearing from you!